New advances in osteoarthritis therapy with stem cells
Osteoarthritis is a rheumatic pathology that damages the articular cartilage. By joining two bones through the joint capsule, the joints are able to move, providing us with functional autonomy. An inner fluid called synovial fluid is usually found within joints, which is produced by the synovial membrane. Articular cartilage covers the ends of the bones that form the joint. As a result of damage to this articular cartilage, pain, stiffness, and functional impairment occur. Osteoarthritis is the most common joint disorder, usually beginning between the ages of 40 and 50, affecting to some degree almost everyone over the age of 80. Typically, osteoarthritis affects the spine, shoulders, fingers, hips, knees, and toe joints.
Stem cell therapies have the potential to treat a broad spectrum of diseases. Whether it’s rhizarthrosis, diabetes, neurodegenerative diseases, spinal cord injuries, or heart disease. By utilizing stem cells, regenerative medicine is capable of repairing tissues in affected areas. The main difference between lipo gem therapy and other treatments for osteoarthritis is that lipogem therapy regenerates cartilage, avoids surgery and its sequelae, and improves the quality of life for patients.
The potential for medical treatments with stem cells and their by-products is currently very high. In the field of sports medicine and traumatology, one of the most outstanding advances has been made for the first time in decades recently: Spanish scientists have achieved a degree of tendon regeneration in 100% of injured patients, resulting in a decrease in pain and a return to sport within two months, and just six months after the trial was completed.
A research performed by the Institute of Regenerative Tissue Therapy (ITRT), published by the prestigious American Journal of Sports Medicine. Demonstrates how this therapy regenerates chronic lesions in the patellar tendon and opens up a new therapeutic option for this tissue, which was considered impossible to regenerate.
In most patients, fat tissue can be harvested minimally invasively (under local or general anesthesia), providing a highly viable MSC population regardless of donor age. Similar to MSCs derived from other tissues, adipose tissue-derived MSCs have regenerative potential. As osteoarthritis is a very common joint disease, and knee osteoarthritis is the most common form, it is necessary to review scientific literature on osteoarthritis treatments with stem cells, like lipogems.
Lipogems Therapy
Lipogems therapy is a novel procedure that enhances the body’s natural ability to heal itself through the innovative power of science and biotechnology. The Lipogems method involves injecting mesenchymal stem cells into the joints. Adipose-derived mesenchymal stem cells have enormous regenerative potential. They also have a regenerative capacity independent of their age. Even older individuals can benefit from this procedure.
Injection of mesenchymal stem cells into the knee, particularly in the early stages of osteoarthritis, can stop the process of inflammation and degeneration, especially in the less advanced stages of the disease. In addition to preventing progressive physical deterioration of the articular cartilage, this treatment contributes significantly to a patient’s well-being and prevents the installation of knee prostheses.
Patellar tendinopathy, physiotherapeutic treatment and stem cell therapy
Injuries to the patellar tendon that connects the kneecap to the tibia are known as patellar tendinopathy or patellar tendinitis. The patellar tendon works with the muscles in the front of the thigh to extend the knee so you can kick, run and jump. Athletes who perform frequent jumping in their sports, such as basketball and volleyball, are most likely to suffer from patellar tendonitis. However, people who don’t engage in jumping sports may develop patellar tendonitis. Patients with patellar tendinitis usually begin treatment with physical therapy to stretch and strengthen their knee muscles.
Strength training with eccentric resistance is one of the most common treatments for tendinopathies. Alternatively, it has been demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) can regenerate injured patellar tendons. Within six months of treatment, it has been observed that the structure of this tissue – which is always difficult to treat – is restored, reaching a regeneration of 40% in all injured persons, with a gradual improvement that eventually becomes complete.
It has been found that traditional management methods, including isometric or eccentric exercises, shock wave therapy, and even surgery, are not effective. As part of a rehabilitation program in chronic patellar tendinopathy, autologous expanded bone marrow mesenchymal stem cells (BM-MSC) or leukocyte-poor platelet-rich plasma (Lp-PRP) may be effective in reducing pain and improving activity levels. Traditional management, which includes isometric or eccentric exercises, shock wave therapy, and even surgery, has limited success. A combination of autologous expanded bone marrow mesenchymal stem cells (BM-MSCs) and leukocyte-poor platelet-rich plasma (Lp-PRP) and rehabilitation may reduce pain and improve activity levels in active participants with chronic patellar tendinopathy.
To learn more about stem cells, cellular therapies and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us
- Published in Corporate News / Blog
Global Stem Cells Group Partners with StemBio to Advance Regenerative Medicine Research and Development
Miami, Florida— Global Stem Cells Group, a leader in regenerative medicine, is thrilled to announce a strategic partnership with StemBio, a renowned leader in the regenerative medicine landscape in Turkey. This partnership aims to propel research and development, conduct clinical trials, and create new products and protocols for the advancement of regenerative medicine.
StemBio, a trailblazer in Turkey, possesses all the necessary licenses and state-of-the-art infrastructure for regenerative medicine, including Bone Marrow Derived MSC, Adipose Derived MSC, Umbilical cord, placenta, Wharton jelly Derived MSC, Synovial Derived MSC, and more. We believe this diverse range of resources demonstrates StemBio’s commitment to excellence, making them one of the foremost facilities for regenerative medicine in Turkey.
This collaboration brings together two powerhouses in the regenerative medicine arena, aiming to break new ground in the research, development, and application of regenerative therapies. We believe the collective expertise and resources of StemBio and Global Stem Cells Group are set to drive innovation and advancements in regenerative care, benefiting patients worldwide.
“We are excited to partner with StemBio and leverage their expertise in regenerative medicine. This partnership should accelerate our mission to provide cutting-edge regenerative solutions to a global audience,” said Benito Novas, head of relationships at Global Stem Cells Group.
We believe the partnership between StemBio and Global Stem Cells Group signifies a significant milestone in the regenerative medicine field. As they combine their strengths and knowledge, they are committed to pushing the boundaries of what is possible in regenerative care and making a lasting impact on patients’ lives.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
About StemBio:
StemBio is a renowned regenerative medicine facility in Turkey, equipped with cutting-edge infrastructure and a commitment to excellence. Holding the necessary licenses for cord blood and tissue banking, as well as advanced engineering solutions, StemBio is a leader in the regenerative medicine landscape.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
International Society for Stem Cell Applications Launches Advanced Turkish Hair Transplant Certification Program in Cancun
Miami, Florida – The International Society for Stem Cell Applications (ISSCA) is thrilled to announce the launch of its newest program, the Advanced Turkish Hair Transplant Certification. This pioneering training and certification initiative will take place from December 8th to 10th at the prestigious Cellular Hope Institute Facility in Cancun, Mexico. Physicians are encouraged to register promptly as the program is expected to fill up quickly.
Turkey has earned a global reputation for providing the finest hair transplants worldwide. Some of the hair transplant experts from Turkey who have developed and perfected this procedure are now willing to share their secrets with any physician who seeks to excel in hair restoration procedures in their home country. The demand for hair regrowth, hair restoration, and hair transplant procedures is growing by the day as men and women realize they do not have to suffer from the embarrassment of thinning hair and bare scalps anymore.
The Advanced Turkish Hair Transplant Certification program offers a comprehensive curriculum encompassing cutting-edge hair transplant procedures. Participants will engage in both theoretical and practical training sessions, helping to assist their mastery of this rapidly expanding field. They will have the extraordinary opportunity to practice hair transplant surgeries under the supervision and guidance of world-renowned experts in the field, including Veysel Cabalar, Asli Uslu, and Emere Tuncinar, who bring their wealth of experience and knowledge to the program.
In addition to hair transplant surgery, the program’s curriculum will cover workshops on advanced hair restoration techniques such as exomes, stem cells, and platelet-rich plasma treatments. Participants will learn how to select suitable patients for these different hair restoration methods and gain hands-on experience in preparing, storing, and administering exosomes, stem cells, and platelet-rich plasma to promote hair regrowth. Armed with this expertise, we believe participants will return to their own clinics with confidence, ready to deliver these transformative procedures for the benefit of their patients.
Dr. Salih Yildirim, ISSCA President, expressed his delight in fulfilling the organization’s mission of expanding the reach of new regenerative medicine technologies to doctors and patients worldwide: “The Advanced Turkish Hair Transplant Certification program exemplifies our commitment to advancing the field of regenerative medicine. We are proud to provide doctors with the tools and knowledge to bring the latest hair restoration techniques to their patients.”
Benito Novas, ISSCA Vicepresident , added, “We are excited to bring this groundbreaking Turkish training to Cancun, offering local doctors and physicians across Latin America the opportunity to learn from the best. Our collaboration with the Cellular Hope Institute Facility underscores our dedication to providing exceptional educational experiences that benefit medical professionals and patients alike.”
The program will include theoretical sessions on scalp and hair follicle anatomy, patient evaluation, and surgical preparation for hair transplant procedures. Detailed workshops on graft extraction and implantation techniques will also be conducted, enabling participants to refine their skills and achieve realistic, outstanding results. From patient evaluations to postoperative care protocols, the hands-on surgical sessions will encompass every aspect of the hair transplant process.
The Advanced Turkish Hair Transplant Certification program by ISSCA offers an invaluable opportunity for doctors seeking to excel in the field of hair transplantation. Participants will gain comprehensive knowledge, refine their surgical techniques, and stay abreast of the latest advancements in hair regrowth, hair restoration, and hair transplants.
To learn more about the Advanced Turkish Hair Transplant Certification program and register for this transformative educational experience, please visit the official ISSCA website at www.issca.com.
About ISSCA
The International Society for Stem Cell Applications (ISSCA) is a multidisciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through advances in regenerative medicine. By bringing together worldwide researchers and healthcare practitioners, ISSCA aims to bridge the gap between cutting-edge scientific research and compassionate, effective patient care.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
ISSCA is Pleased to Announce the Launch of its Comprehensive Online Course in Regenerative and Functional Medicine for Obesity Management
The International Society for Stem Cell Application (ISSCA) is proud to announce the launch of its latest online course, “Curso en Medicina Funcional Regenerativa y Obesidad / Course in Functional Regenerative Medicine and Obesity.” This comprehensive course is designed to provide students with a deep understanding of various aspects of obesity treatment, metabolic syndrome, and post-procedure management of patients.
“This course should provide students with the knowledge and skills necessary to succeed in the field of regenerative and functional medicine,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “We are committed to providing students with a comprehensive understanding of the latest advancements in the field and how to effectively care for patients”.
The course covers various key concepts of regenerative and functional medicine for obesity management, and gastric balloon, a safe and effective non-surgical treatment, as one of them. The course will feature in-depth insights into the fundamentals of this procedure and how they can be used to help patients achieve and enjoy healthy weight loss. Additionally, post-procedure management approaches and protocols, will be covered.
Apart from balloon therapy, the course will also explore a wide range of other related topics, such as vitamins, exosomes, trace elements, minerals, hydrolyzed collagen, and more, and their significance in obesity management. These topics should prove useful to practitioners and course other course attendees in understanding metabolic syndrome and the best post-procedure practices for managing patients.
The course will be taught by two highly experienced and well respected professionals in the field of medicine:
Dr. Mario Ojeda, Director and Member of the Chilean Society of Aesthetic Medicine and Surgery (SOCHIMCE). An international reference and renowned expert in various areas, including obesity, intragastric balloons, endoscopic gastroplasty, stem cells, gastroenterology, digestive endoscopy, and colonoscopy, Dr. Mario Ojeda is “pleased to be part of this comprehensive online course and to provide students with the necessary knowledge and skills to advance the field of regenerative and functional medicine.”
Dr. Silvina Pastrana, Head of the ISSCA chapter in Latin America. She is a specialist in general surgery and has extensive experience in aesthetic and anti-aging medicine, orthomolecular medicine and nutrition, cellular therapies, and more. As a trainer in cellular therapies, she is well-equipped to provide students with a comprehensive understanding of the latest advancements in the field.
ISSCA is committed to advancing knowledge in regenerative and functional medicine for better obesity management. This comprehensive online course should provide physicians and specialists with a complete understanding of the latest advancements in the field and how to effectively manage patients, post-procedure.
For more information about the course and how to enroll, please visit the ISSCA visit the ISSCA website, send an email to info@stemcellsgroup.com, or call +1305 560 5337
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advancements in regenerative medicine. It is the educational division of the Global Stem Cells Group focused on promoting excellence and standards in the field of regenerative and functional medicine.
Through training and advancement courses, ISSCA aims to encourage physicians and specialists to practice new and advanced regenerative medicine approaches to benefit patients globally. It also ensures that practitioners learn, meet, and adhere to the necessary regenerative medicine standards and certifications.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Atherosclerosis: The Most Common Form of Arterial Occlusive Disease in Adults
Introduction to Atherosclerosis
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
Atherosclerosis Obliterans Grade IV
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies, as well as pioneering clinical studies, indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Case Studies and Research
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
Research Findings on Atherosclerosis Obliterans Grade IV
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication, and ankle-brachial pressure index.
We still need to explore a lot of ground in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us.
- Published in Corporate News / Blog
Global Stem Cells Group Announces the Opening of a Multi-Specialty Regenerative Medicine Center in Cancun
Global Stem Cells Group has just announced the official opening of a new multi-specialty regenerative medicine center in Cancun. The new center is intended to incorporate different treatments based on regenerative medicine as well as to serve as a multi-specialty training center in the field of regenerative medicine and cellular therapies, offering doctors and patients the most advanced treatments in cell therapy worldwide.
The Cellular Hope Institute, as this facility was named, will also strive to pursue several objectives that will benefit patients and medical experts worldwide. It is expected to be a medical hub that will offer the best treatments for patients suffering from multiple conditions such as autoimmune deficiencies, sports injuries, chronic degenerative diseases and pediatric diseases.
Benito Novas says. “Our goal is to solve the problem and alleviate the condition, not just attempt to treat it. We are committed to offering top-notch technology available and quality care, emphasizing that our patients are always our number one priority. Our highly qualified team of experts are always ready to assist you at Cellular Hope Institute.”
The Center utilizes comprehensive stem cell treatment protocols that employ well-targeted combinations of Exosomes, allogeneic human Mesenchymal cells, autologous bone marrow and Adipose derived stem cells to treat the diseases and conditions listed above. The treatment plans are mostly focused on a systemic or whole-body approach to ensure patients receive the highest quality and quantity of cellular products available today.
Cellular Hope Institute will also be a center that will offer specialized regenerative medicine courses for physicians. Primarily, it is expected to be a resource center that will train doctors to incorporate modern regenerative medicine practices into their offices.
Our focus is to incorporate multiple specialties into separate programs within this training hub. Industry experts are expected to join the facility and offer the latest information about various compounds in the stem cell market, such as Mesenchymal stem cells, umbilical cord derived products, exosomes and many other stem cell products. We plan to target physicians who want to incorporate the treatment solutions into their practices, and the separate programs are designed to reach a wide array of practitioners.
In addition, Cellular Hope Institute also expects to have a fully functional manufacturing laboratory that seeks to elaborate the cellular products. The laboratory is already equipped with the latest and innovative technology to ensure it offers the best stem cell products and treatments. The facility will have enough capacity to store and distribute cellular products, including cells and exosomes. We expect it to be the primary supply center for doctors all over Mexico. The inauguration will mark a step closer to pursuing cell therapy, regenerative medicine, and modern tissue engineering options globally.
The opening of this center is an effort by Global stem Cells Group to continue its mission to reduce the suffering of patients and offer a new healing alternative. It is the commitment of scientists and doctors who believe in the potential of regenerative medicine as a standard treatment that should be in every doctor’s office worldwide.
To learn more about the cellular hope institute, visit its website here: https://cellularhopeinstitute.com/
- Published in Press Releases
Announcement of Training in Fort Lauderdale, Florida by The Global Stem Cells Group
Recently, the Global Stem Cells Group announced plans to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practices. MIAMI, 4–5 November 2022—Global Stem Cells Group, a multidisciplinary community of scientists and physicians that are working together to cure diseases and relieve human pain through the advancement of the field of regenerative medicine, announced today a plan of training in Fort Lauderdale on November 4th and 5th. This training aims to equip physicians with the value and knowledge behind incorporating regenerative medicine into their own clinical practice. Benito Novas, CEO of GSCG, is confident that the event will bring together a group of:
- Doctors are seeking training, products, and equipment in regenerative medicine.
- Doctors who care for patients with conditions that can be treated with cell therapies
- Aesthetic doctors.
- Doctors who want to be up to date with the latest technologies and protocols
- Doctors with an interest in new research on stem cells, MSC, Exosomes, and medical networks want to attract more clients.
The training course is intended to cover:
- Hands-On portion: Doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures being performed a few feet away and then get the opportunity to try them for themselves.
- Review of stem cell biology
- Characterization of cells, cell products, cytokines, and growth factors, as well as their capacity for regeneration.
- Laboratory Processes
- Clinical applications
- Product validation
- Practice Management
- Patient acquisition
The International Society for Stem Cell Application (ISSCA) has done intensive research on this topic and the team will take a lead in educating, training, and certification during the event. As a medical speciality, regenerative standards and certification are very important, which is why ISSCA will provide certificates after the training. By the end of the training course, you will understand everything you need to know to add adult stem cellbased procedures to your existing practice. As before, the united efforts of the seven major medical corporations will provide practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards. To find more about the courses and to make reservations for this particular event, head on to their website www.issca.us/autologous-miami-november/ .us email info@stemcellsgroup.com or dial +1305 560 5337.
About ISSCA
ISSCA is a multidisciplinary community that brings together scientists and physicians, all of whom aspire to treat diseases and relieve human pain through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through innovations made to the speciality of regenerative medicine. The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, training, research, education, and certification.
As a medical speciality, regenerative medicine standards and certifications are very important, which is why ISSCA provides certification training globally. This is because they want to encourage more physicians to practice regenerative medicine and make it accessible to benefit patients both nationally and worldwide. Incorporated under the Republic of Korea as a nonprofit entity, the ISSCA’s main goal is to promote excellence and standards in the field of regenerative medicine. As a physician, missing this chance to book a personalized hands-on training session must cost you dearly. Contact + 1 305 560 5337 to book as early as possible.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Releases
ISSCA Offers New Online Post-graduate Program in Regenerative Medicine and Advanced Therapies
With video lectures and additional tools from some of the most respected names in today’s stem cells field, the course arms practitioners with the necessary knowledge and resources to offer innovative regenerative medicine treatments in their existing practices.
MIAMI, Florida— The International Society for Stem Cell Application (ISSCA) has announced it has launched a new online Post-graduate Program in Regenerative Medicine and Advanced Therapies. The course adds to the group’s already existing robust offering of onsite and online courses designed to give physicians looking to incorporate regenerative medicine protocols into their practices the education and tools necessary to do so.
Regenerative medicine has been increasingly gaining attention in today’s fast-paced medical world. As more researchers and physicians become interested in studying the field and introducing treatment protocols into their practices, it can be difficult to know which products and practices yield the best results for patients seeking these treatments for relief from degenerative diseases, noted Dr. Silvina Pastrana, main professor of the program and medical director of the stem cell center in Buenos Aires. Knowing which products work for which conditions and how to safely administer them to maximize results are key in leading a successful regenerative medicine practice.
With the new online Post-graduate Program in Regenerative Medicine and Advanced Therapies and others offered by the ISSCA, physicians will learn these valuable protocols and more about product offerings and how to choose the most effective ones. The Post-graduate Program will prepare physicians with the necessary theoretical and practical knowledge needed to effectively and safely secure better patient outcomes when using cellular therapies. With this training, physicians will gain knowledge from leading scientists in the field, learn valuable information on safety standards and quality control from top manufacturers, be positioned to perform these procedures and open a Stem Cell Center practice, join the ISSCA’s network, and enjoy the benefits of an exponentially growing industry worldwide.
Physicians looking to enroll in this online Post-graduate Program and other offerings by the ISSCA are in good hands. The group is widely considered as the global standard bearer when it comes to education and research in the regenerative medicine field. For years, the ISSCA has played a critical role in bridging the gap between the science behind stem cells and regenerative medicine and the practical application of that science in a clinical setting.
“We are pleased to add the online online Post-graduate Program in Regenerative Medicine and Advanced Therapies to our growing number of course offerings designed to deliver the skills and education needed to practitioners eager to implement stem cells treatment protocols into their existing practices,” said Benito Novas, ISSCA VP of Public Relations. “The program gives physicians the skills needed to utilize these highly effective treatments to help patients suffering from degenerative diseases while expanding on the ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA, visit www.issca.us. To learn more about the group’s new online Cellular Therapy course or to register, visit https://cursocelulasmadre.com/cursos-de-certificacion/posgrado-en-medicina-regenerativa-y-terapias-avanzadas/
- Published in Press Releases
GSCG Announces Upcoming Stem Cell Training Course in Dubai
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced plans for a training in Dubai, UAE on November 11th-12th.
This training will be one of the second one of 2022, reaffirming the Global Stem Cells Group’s presence in Europe as a key player in the field of regenerative medicine. Members from both Global Stem Cells Group & the International Society for Stem Cell Application’s Dubai Chapter will be there to assist in expanding research for and the practice of regenerative medicine across Europe.
“We hope that more and more physicians and clinics will take up the benefits of regenerative medicine.As we continue to train patients with the GCell Machine, ” Says Benito Novas, founder and CEO of the Global Stem Cells Group
This training is intended to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practice. This includes a theoretical portion that goes over basic regenerative medicine biology and its application, but also includes a Hands-On portion in which doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures be performed just a few feet away, and then get the opportunity to try it for themselves.
This training will also teach physicians how to utilize the GCell Machine to perform regenerative medicine therapies. GCell is a tissue homogenization device that is revolutionizing the future of regenerative medicine. It is an extremely compact, all-in-one unit that can homogenize and isolate the stem cells from an adipose sample. GCell’s process of homogenizing with a system of precise blades and filtering ensures that the sample can be processed within an hour, with little input from the physician when the machine begins to do its work.
Once the process is over, the end result is a final product that can be administered to patients within an hour after the initial tissue extraction. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and the shortened timespan and simplicity of the procedure is something that both doctors and their patients will greatly appreciate.
If you are interested in enrolling in this upcoming event, or to learn more about the different training opportunities available, you can visit us at our training website.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Releases
How Exosome Therapy Differ from Stem Cell Therapy
Exosomes are potent microvesicles released by adult mesenchymal stem cells. They have the ability to help restore cells in the body by improving cell to cell communication.
Exosomes are not cells, and they are smaller than cells. When compared to adult stem cells, exosomes have much more growth factors which give them a better clinical and aesthetic potential than stem cells.
It’s a cell-free cell therapy, this makes it safer compared to other cellular therapy, because there’s no risk of rejection in graft Vs host.
Unlike some other cellular therapies, exosomes do not produce host graft reactions, because they do not carry HLA genetic information and are not cells but extracts of the cells (released by cells).
Exosomes have a superior regenerative capacity, because they are obtained from newborn umbilical cord tissue mesenchymal cells, which means they have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body.
Exosomes improve the signaling between cells, thereby making them useful to revitalize, rejuvenate, restore, and cause anti-inflammatory effects in the body.
When compared to autologous adult stem cells, exosomes have much more healthy growth factors which gives them a better clinical and aesthetic potential than stem cells.
Exosomes are less complicated products to transport because the cells used in cellular therapy must be applied to the patient very quickly because they are live cells. In the laboratory, once they are thawed the doctors have limited time to apply them. However, with exosomes, they last longer, because as they are proteins they do not denature and can last for longer periods.
Exosomes is a superior product to autologous treatments because they do not require a surgical procedure, they come in a vial that can be injected directly, significantly reducing the risk and complications of a surgical procedure.
It is a superior product to autologous stem cell therapy because the patient’s cells have the same age and the same quality. For example, if a patient is a smoker and intoxicated, obviously the health of his cells is not the best. That is why the most indicated product is a donor product that is pure and free of toxins.
Mesenchymal cell-derived exosomes are preferably used in regenerative medicine. These cells are excellent regenerative cells due to their multipotent nature, therefore MSCs derived exosomes are superior to other exosomes products.
The Cellgenic lyophilized exosomes are derived from mesenchymal cells, which makes it superior to other exosome products, because mesenchymal cells have superior and excellent regenerative capacity.
This is why exosome therapy, especially Cellgenic lyophilized exosomes should be a doctor’s first choice.
- Published in Corporate News / Blog
